Analysts have been eager to weigh in on the Healthcare sector with new ratings on Addex Therapeutics (ADXN – Research Report) and Belite Bio, Inc. ADR (BLTE – Research Report).
Addex Therapeutics (ADXN)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Addex Therapeutics. The company’s shares closed last Monday at $1.22, close to its 52-week low of $0.86.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on Addex Therapeutics is currently a Hold rating.
See today’s best-performing stocks on TipRanks >>
Belite Bio, Inc. ADR (BLTE)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Belite Bio, Inc. ADR today and set a price target of $58.00. The company’s shares closed last Monday at $25.10.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Belite Bio, Inc. ADR has an analyst consensus of Moderate Buy, with a price target consensus of $57.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADXN:
- Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), Portage Biotech Inc (PRTG) and IN8bio (INAB)
- Is Olin (NYSE:OLN) a Good Stock to Buy?
- Goldman Sachs Reaffirms Their Hold Rating on Uniper SE (UNPRF)
- Iris Energy (IREN) Receives a New Rating from H.C. Wainwright
- H.C. Wainwright Keeps Their Buy Rating on Brainsway (BWAY)
